Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347266 | 0.88 | SLC10A2 (0.55) | SLC10A2 | |
| SCHEMBL366859 | 0.88 | SLC10A2 (0.67) | SLC10A2 | |
| Iodide SCHEMBL7572172 | 0.87 | SLC10A2 (0.63) | SLC10A2 | |
| SCHEMBL6838866 | 0.87 | SLC10A2 (0.64) | SLC10A2 | |
| SCHEMBL348627 | 0.87 | SLC10A2 (0.53) | SLC10A2 | |
| SCHEMBL6838860 | 0.85 | SLC10A2 (0.59) | SLC10A2 | |
| SCHEMBL6843175 | 0.85 | SLC10A2 (0.58) | SLC10A2 | |
| Iodide SCHEMBL6838763 | 0.84 | SLC10A2 (0.59) | SLC10A2 | |
| SCHEMBL6838829 | 0.83 | SLC10A2 (0.54) | SLC10A2 | |
| SCHEMBL27307368 | 0.83 | SLC10A2 (0.67) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719768-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2006-11-08 | — | — | EP | disclosed |
| CN-1678597-A | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORP (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | PHARMACIA CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | G.D. SEARLE LLC | 2002-12-05 | — | — | US | disclosed |
| WO-2002008211-A2 | BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | G.D. SEARLE, LLC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | SLC10A1, ABCB11, SLC10A2 | SLC10A2 3/4885 |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | SLC10A2 43/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | SLC10A2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.